Neuraltus’ programs focus on novel drug molecules with promising mechanisms of action representing first-in-class approaches to treating the Company’s target disease indications.
|Preclinical||Phase 1||Phase 2||Phase 3|
NP001, a novel, proprietary approach that regulates macrophage activation, targets diseases including ALS, Parkinson’s disease, Alzheimer’s disease and multiple sclerosis. NP001 is designed to transform select immune cells (macrophages) from a neurotoxic state to a neuroprotective state, normalizing the cellular environment of critical nerve cells.
Neuraltus’ focus on macrophages is based on the recent understanding of the fundamental role of inflammation and macrophages in neurological diseases. Runaway inflammation has been associated with many of the symptoms seen in severe neurological diseases and is believed to play a major role in the progression of these diseases. Treating inflammation of the central nervous system (neuroinflammation) provides a robust platform for addressing upstream disease mechanisms associated with the most severe neurodegenerative diseases
NP003 is an orally bioavailable, small molecule designed to treat lysosomal storage disorders such as Fabry's disease and Gaucher's disease. NP003 works by limiting the ability of harmful lipids to collect in the cells of lysosomal storage disorder patients. NP003 is expected to be synergistic with current enzyme replacement therapies. In addition, because it crosses the blood-brain barrier, NP003 is expected to provide central nervous system protection from abnormal lipid accumulation. NP003 may also inhibit glycolipid-induced aggregation in the brain of α-synuclein protein, believed to be a primary cause of Parkinson's disease.